Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL294303 | 0.92 | POLB (0.39) | LMNAHTTPOLBALDH1A1HSD17B10 | |
| SCHEMBL294845 | 0.91 | POLB (0.42) | LMNAHTTPOLBALDH1A1HSD17B10 | |
| SCHEMBL294925 | 0.90 | POLB (0.45) | LMNAHTTPOLBALDH1A1HSD17B10 | |
| SCHEMBL295358 | 0.85 | MEN1 (0.46) | LMNAHTTPOLBALDH1A1HSD17B10 | |
| SCHEMBL2776020 | 0.80 | KDM4E (0.46) | LMNAHTTPOLBALDH1A1MEN1 | |
| SCHEMBL2968217 | 0.76 | ALDH1A1 (0.50) | LMNAPOLBALDH1A1HSD17B10MEN1 | |
| SCHEMBL294145 | 0.75 | MEN1 (0.44) | LMNAHTTPOLBALDH1A1HSD17B10 | |
| SCHEMBL1969717 | 0.75 | ALDH1A1 (0.39) | LMNAPOLBALDH1A1HSD17B10MEN1 | |
| SCHEMBL1970540 | 0.75 | ALDH1A1 (0.41) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL294064 | 0.74 | KMT2A (0.47) | LMNAHTTPOLBALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344004-B2 | Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | SANOFI (FR) | 2013-01-01 | — | — | US | disclosed |
| US-8344004-B2 | Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | SANOFI (FR) | 2013-01-01 | — | — | US | disclosed |
| EP-2240474-B1 | CYCLIC PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2012-03-14 | — | — | EP | disclosed |
| US-20110224263-A1 | Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2011-09-15 | — | — | US | disclosed |
| US-20110224263-A1 | Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2011-09-15 | — | — | US | disclosed |
| US-20110224263-A1 | Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2011-09-15 | — | — | US | disclosed |
| WO-2009080223-A1 | CYCLIC PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224263-A1 | Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | PPARD, PPARG, PPARA | LMNA 1328/4885HTT 1483/4885POLB 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.